Home About Us Contact Us

 

Table of Content - Volume 9 Issue 1 - Januray 2018


 

Clinical profile of patients with Hepatitis A virus infection at tertiary care teaching hospital

 

Sanjay Thorat1*, Tejas Rane2, Akshay Kulkarni3, Aniket Avhad3

 

1Professor, 2Junior Resident, 3Junior Resident, Department of Medicine, Krishna Institute of medical sciences Deemed to be University.Karad.415110, INDIA.

Email: drtejasrane@gmail.com

 

Abstract              Background: This study was undertaken to study clinical profile of patients with Hepatitis A virus infection at a tertiary care teaching hospital, Krishna Institute of Medical Sciences, Karad. Methods: It was a retrospective study for duration of one year (July 2017 to June 2018). All patients with age more than 15 years, diagnosed as HAV positive were included in the study. Medical records were studied for detailed clinical history, physical examination findings and laboratory findings. Total 40 patients were included in the study. Results: Data collected from this study revealed that majority of patients were from age group 15-25 years. Maximum number of patients presented with anorexia (80%) followed by fever (77.5%) and nausea (72.5). About75% of patients had icterus and hepatomegaly was seen in 40% of patients. Laboratory reports revealed that deranged LFTs with average SGPT value of836 and SGOT value of 779.average duration of stay in hospital was 7 days. Higher bilirubin levels were seen in older patients. There were 2 patients co infected with hepatitis B and one patient co infected with HIV. Conclusion: Although hepatitis A infection rarely results into chronic hepatitis or death, severity of symptoms usually results into longer duration of hospitalization. Hence prevention of this disease by means of vaccination or by improving personal hygiene to prevent feco-oral spread of the disease will be more effective to reduce social and financial burden due to hospitalization.

Key Word: Hepatitis A virus infection.

 

INTRODUCTION

Hepatitis is a general term meaning inflammation of liver and can be caused by variety of different viruses such as hepatitis A, B, C, D and E. Since development of jaundice is characteristic of liver disease, correct diagnosis can only be made by testing patients sera for the presence of specific antiviral antibodies or antigens.1, 2 The incidence of infection with these five viruses is generally lowest in industrialised and developed countries and highest in less developed regions. Hepatitis A virus and hepatitis E virus spread mainly through faeco-oral route and the three hepatitis B, C and D virus spread mainly by exposure to blood.3 All the viruses can cause acute illness characterised by nausea, malaise, abdominal pain and jaundice.4 Regional trends are variable and play an important role in clinically suspecting the disease. Hence the current study is undertaken to study the clinical profile of HAV viral hepatitis at a tertiary care hospital.

 

MATERIALS AND METHODS

  • All patients with age more than 15 years, diagnosed as HAV positive during study period (July 2017-June 2018) were included in the study. Total 40 patients were included.
  • This was hospital based retrospective study, carried out in tertiary care teaching hospital.
  • A detailed history, physical examination findings, laboratory investigation and treatment details were obtained from patients records.
  • The patient record were analysed for age, sex, duration of hospitalization, symptoms, signs, treatment given and clinical outcome.
  • This was a retrospective observational and non-interventional study conducted at the teaching hospital, , Krishna Institute Of Medical Sciences, Karad, during a one year period.
  • Ethical Clearance was obtained from the institutional ethics committee.

 

RESULTS

In our study total 40 individuals with confirmed diagnosis of HAV hepatitis were included. Of these 29 patients were male and 11 females with male to female ratio being 2.63:1. Most commonly affected age group was 15-25 years (n=20) followed by 26-30 years (n=14). Lowest number of patients were in age group of > 45 years (n=1). Median age of the population included in study was 25 years. Mean age in our study was 26.6 ± 9.47 Years, with the minimum age of 16 years and maximum age of 56 years.

Table 1: Age group and gender wise distribution

Age group

Male

Female

Male %

Female %

15 – 25

16

4

40

10

26 – 35

9

5

22.5

12.5

36 – 45

3

1

7.5

2.5

>45

1

1

2.5

2.5

Total

29

11

72.5

27.5

 

 

Table 2: Haematological profile of the study individuals

Hb

Number

Percentage

<10 g%

10

25

>10 g%

30

75

Platelet Count

 

 

<1.5 Lakh

12

30

>1.5 Lakh

28

70

TLC

 

 

<4000

12

30

4000 – 11,000

20

50

>11,000

8

20

25% of the patients had anemia, average Hb level was 12.06 ± 2.2 gm/dl. 30% patients had platelets less than 1.5 lakh. In TLC, 30% patients had leukopenia while 20% had leucocytosis. Mean TLC was 7747.5 ± 3339.43 while mean platelet count in our patients was 1.6 ± 0.29 Lacs. Most common chief complaint at the time of presentation was anorexia (80%), followed by fever (77.5%), nausea (72.5%), dark coloured urine, abdominal discomfort and pruritus (45%). Of all the patients included in the study, one patient had presented with seizure episode. The average length of stay in hospital was 6±1.3. days, with only 4 patients who had to stay for more than 15 days, maximum duration of stay was 27 days while minimum stay was 3 days.

 

 

Table 3: Symptoms of study individuals

Symptoms

Number

Percentage

Anorexia

32

80

Fatigue

20

50

Nausea

29

72.5

Vomiting

16

40

Dark Coloured Urine

18

45

Yellowish Sclera

12

30

Fever

31

77.5

Abdominal Discomfort

18

45

Diarrhoea

18

45

Pruritus

17

42.5

Joint Pains

6

15

Rashes

6

15

Convulsion

1

2.5

Others

5

12.5

 

Table 4: Signs of the disease

Sign

Number

Percentage

Icterus

30

75

Pallor

10

25

Hepatomegaly

16

40

Splenomegaly

5

12.5

The most common sign observed was icterus in 75% of the patients followed by Hepatomegaly in 40%, pallor in 25% and splenomegaly in 12.5% of the patients.

 

Table 5: Liver profile

Parameter

Number

Percentage

1. Total Serum Bilirubin (mg/dl)

 

 

0.2 – 1

1

2.5

>1

39

97.5

2.Serum Bilirubin Direct (mg/dl)

 

 

0.3 – 0.8

1

2.5

>0.8

39

97.5

3. SGPT (IU/L)

 

 

0 – 40

2

5

>40

38

95

4. SGOT (IU/L)

 

 

0 – 40

1

2.5

>40

39

97.5

5. Serum Albumin (g %)

 

 

3.5 – 4.5

24

60

<3.5

16

40

6. Alkaline Phosphatase (IU/L)

 

 

<90

18

45

90 – 180

11

27.5

>180

1

2.5

8. Prothrombin Time (Sec)

 

 

<15

30

75

>15

10

25

Almost 97.5% study individuals presented with deranged liver function test. Average total bilirubin was 8.35 with SD of 1.88 mg/dl. Laboratory reports revealed that deranged LFTs with average SGPT value of 836.4 ± 147.46 and SGOT value of 779.1 ± 153.54. 95% of the participants had SGPT levels of > 40 IU/L, while 97.5% patients had SGOT levels of > 40 IU/L. Serum albumin was <3.5 g% in 40% of the participants while Alkaline phosphatase was seen 90 – 180 IU/L in 27.5% and >180 in 2.5% of the study individuals. The serum prothrombin time was raised to >15 seconds in 25% of the individuals.

 

DISCUSSION

All hepatitis viruses (A, B, C, D and E) can cause acute illness characterised by nausea, malaise, abdominal pain and jaundice.4 Still majority of population in developing countries like India are deprived of basic needs of life like purified drinking water. Incidence of viral hepatitis, especially those spread by feco-oral route is high.  Hepatitis A virus causing hepatitis constitutes major part of such feco-orally spread hepatitis.4 The HAV is transmitted through the faeco-oral route, either from person to person or through contaminated food or water. It is strongly related to personal hygiene and lower standards of living.5,6  The variability in nature of the disease regarding its onset, presenting symptoms, clinical course and development of complications in viral hepatitis are important aspects which require clinical attention from time to time.4 Regional trends are variable and play an important role in clinically suspecting the disease. Hence the current study was to undertake the clinical profile of HAV viral hepatitis at a tertiary care hospital. The 50% of our study population were from the age group of 15-25 years, followed by 35% from the age group of 26-35 years, thus a majority of our study population was from young adult group. In a similar study done by Randy Adiwinata et al in Jakarta, Indonesia (2017) it was observed that low hospitalization rates of patients with the hepatitis A infection were mainly represented by young productive age. Similar result was obtained in our study with maximum number of patients being in the age group of 15-25 years. Routine Hepatitis A vaccinations in young adults, as a part of the national immunization program, will be beneficial as it is highly protective, it increases productivity by reducing absenteeism from work, and decreases the health cost. There were 2 patients in the study co-infected with hepatitis B and one patient co infected with HIV.7 Anaemia was observed in 25% of our study population, with average Hb level was 12.06 ± 2.2 gm/dl, 30% patients had leucopenia while 20% had leucocytosis and 30% cases had platelet counts less than 1.5 lacs. A Mocroft13, in their study also found association of HAV infection with anaemia. Myron J. Tong et al found that The clinical spectrum of acute hepatitis A virus (HAV) infection is varied and includes silent infection detected only by viral serologic testing, subclinical infection revealed by abnormal liver tests, clinically apparent hepatitis and rarely, fulminant hepatitis, which is associated with coma and occasionally death. While most infants and children have silent or subclinical infections, the majority of adults develop symptoms and signs of acute disease. Similar results were obtained in our study with patients presenting with anorexia (80%), followed by fever (77.5%), nausea (72.5%), dark coloured urine, abdominal discomfort and pruritus (45%). Atypical manifestations such as relapse, cholestasis, rash, and arthralgia also have been described in patients with hepatitis A, but the pathophysiology of these phenomena has not been elucidated. Amongst the signs observed in our patients, most common was icterus (75%), followed by hepatomegaly (40%), pallor (25%) and splenomegaly (12.5%). The classic manifestations in HAV infection are elevated levels of liver enzymes, the appearance of dark urine, dark-coloured stools, and jaundice.14These clinical manifestations are due to the host immunologic response against the viral infection, which can induce acute liver injury. Intrahepatic inflammation impairs transport of conjugated bilirubin, leading to an accumulation of bilirubin in the skin and sclera, which causes jaundice.15 In the similar study done by Myron J. Tong et al, it was seen that in adults, HAV infection has been reported to cause more severe liver disease such as cholestatic and relapsing hepatitis, which has a prolonged course.8,9 However, mortality due to HAV is extremely low (0.05%–0.1%).10,11   In our study, no mortality was observed due to HAV infection. Only 4 patients had hospital course longer than 15 days. With an average length of stay of 6 ± 1.3 days. HAV super infection in patients with pre-existing chronic liver disease has been reported to cause liver failure and death, particularly in the West. Therefore, routine HAV vaccination is recommended in the West for patients with chronic liver disease.12 Results from our laboratory testing showed a marked increase of ALT compared to AST and elevated levels of direct bilirubin, decreased serum albumin; these are similar to the results of other studies.  We had 97.5% patients with total serum bilirubin >1, 95% with SGPT > 40 and 97.5% with SGOT > 40. Prothrombin time was increased >15 seconds in 25% patients. Study done by Randy Adiwinata et al in Jakarta, Indonesia (2017) found that the targeted age group may benefit from receiving routine hepatitis A vaccinations. The average length of hospitalisation in the sample group was 6 days and there are no specific therapies available to shorten the length of illness.8 The only effective prevention of hepatitis A is via vaccination, with the vaccine having a 94-95% protective efficacy and predicted protection up to 45 years.14 Vaccination has been proven effective at maintaining a lower risk of infection as per studies conducted on toddlers in Israel.16 Therefore, WHO recommends that vaccine should be administered universally in low endemic countries like America, Australia, and Northern and Western Europe.  The extremely high prevalence of anti-HAV antibody in the general population in India implies that a mass immunization programme against HAV would not be cost-effective. As the anti-HAV test is cheaper than the HAV vaccine, it may be cost-effective to do this test before administering the HAV vaccine.1   The changing seroprevalence of HAV infection all over the world time to time demands more data on HAV infection from institutions and research centres to help tackle the epidemic.14-16 This study thus was an attempt to generate insight into the clinical and laboratory findings of HAV infected patients.

 

CONCLUSION

Although hepatitis A infection rarely results into chronic hepatitis or death, severity of symptoms usually results into longer duration of hospitalization. Hence prevention of this disease by means of vaccination or by improving personal hygiene to prevent feco-oral spread of the disease will be more effective to reduce social and financial burden due to hospitalization.

 

REFERENCES

  1. Satsangi S, Dhiman R. Combating the wrath of viral hepatitis in India. Indian J Med Res. 2016; 144(1):1.
  2. Kumar M, Sarin SK. Viral hepatitis eradication in India by 2080- gaps, challenges and targets. Indian J Med Res. 2014; 140: 1-4.
  3.  Jain P, Prakash S, Gupta S, Singh KP, Shrivastava S, Singh DD, et al. Prevalence of hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis D virus and hepatitis E virus as causes of acute viral hepatitis in North India: a hospital based study. Indian J Med Microbiol. 2013; 31(3):261-5.
  4. International Journal of Advances in Medicine Birajdar SV et al. Int J Adv Med. 2017 Apr;4(2):412-416
  5. Lee HC, Ang LW, Chiew PKT, James L, Goh KT. Changing epidemiological patterns of hepatitis A infection in Singapore. Ann Acad Med Singapore. 2011; 40: 439-47.
  6. Nalbantoglu B, Donma MM, Ozdilek B, Karasu E, Nalbantoglu A. Shifting epidemiology of hepatitis A infection and vaccination status of children aged 6 months-12 years: time for mass vaccination. Iran J Pediatr. 2013; 23: 276-80.
  7. A Clinical Profile of Hepatitis A Patients in Jakarta, Indonesia Randy Adiwinata1, Andi Kristanto1, Timoteus Richard1, Daniel Edbert1, Frida Angelina2, Eppy3, Ifael Yerosias Mauleti4, Soroy Lardo5, Iman Firmansyah6, Rika Bur7, Titos Ahimsa8, Erni Juwita Nelwan
  8. Brown GR, Persley K. Hepatitis A epidemic in the elderly. South Med J 2002; 95:826–33.
  9. Lednar WM, Lemon SM, Kirkpatrick JW, Redfield RR, Fields ML, Kelley PW. Frequency of illness associated with epidemic hepatitis A virus infections in adults. Am J Epidemiol 1985; 122: 226–33.
  10.  Rakela J, Redeker AG, Edwards VM, Decker R, Overby LR, Mosley JW. Hepatits A virus infection in fulminant hepatitis and chronic active hepatitis. Gastroenterology 1978; 74: 879–82.
  11. Bianco E, Stroffolini T, Spada E, Szklo A, Marzolini F, Ragni P, et al. Case fatality rate of acute viral hepatitis in Italy (1995–2000): An update. Dig Liver Dis 2003;35:404–8
  12. Vento S, Garofano T, Renzini C, Cainelli F, Casali F, Ghironzi G, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998;338:286–90.
  13. Mocroft A, Kirk O, Barton SE, Dietrich M, Proenca R, Colebunders R, Pradier C, Ledergerber B, Lundgren JD, EuroSIDA study group. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. Aids. 1999 May 28; 13(8):943-50.
  14. Acharya SK, Batra Y, Bhatkal B, Ojha B, Kaur K, Hazari S, Saraya A, Panda SK. Seroepidemiology of hepatitis A virus infection among school children in Delhi and north Indian patients with chronic liver disease: implications for HAV vaccination. Journal of gastroenterology and hepatology. 2003 Jul; 18(7):822-7.
  15. Tanaka J. Hepatitis A shifting epidemiology in Latin America. Vaccine. 2000 Feb 18; 18: S57-60.
  16. Mall ML, Rai RR, Philip M, Naik G, Parekh P, Bhawnani SC, Olowokure B, Shamanna M, Weil J. Seroepidemiology of hepatitis A infection in India: changing pattern. Indian journal of gastroenterology: official journal of the Indian Society of Gastroenterology. 2001; 20(4):132-5.

 

 





 


 


 


 









Policy for Articles with Open Access
Authors who publish with MedPulse International Journal of Anesthesiology (Print ISSN:2579-0900) (Online ISSN: 2636-4654) agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.